Bayer AG: acquisition of Vividion Therapeutics
The pharmaceutical and life-science solutions firm has purchased Vividion, a US-based biotech company. The purchased firm specializes in using various discovery technologies to unlock high-value, challenging targets with precision therapeutics, using its chemoproteomics platform.
Stefan Oelrich, member of Bayer AG’s board of management and president of its pharmaceuticals division, said, “Vividion’s technology is the most advanced in the industry, and it has demonstrated its ability to identify drug candidates that can target challenging proteins. Together with Bayer’s existing know-how, we will be able to develop first-in-class drug candidates, increasing the value of our pipeline.”